Semaglutide initiates Phase III clinical trial of NASH in China
On July 27, 2021, Novo Nordisk registered the Phase III clinical trial of Semaglutide in the treatment of non-alcoholic steatohepatitis (NASH) on the drug clinical trial registration and information disclosure platform website.
This international multi-center Phase III clinical program enrolled 1285 patients with NASH, including 1,200 from abroad and 85 from China. A total of 399 clinical centers around the world participated, including 24 in China (including 4 in Taiwan).
Semaglutide has been approved by the FDA for the treatment of type 2 diabetes and obesity, Alzheimer's disease (3700 cases of phase III clinical), NASH (1285 cases of phase III clinical), cardiovascular (CVD), chronic kidney disease (CKD), etc. Many important indications are under active development, and organs such as the brain, liver, heart, and kidney will all benefit from semaglutide.
In 2020, the sales of semaglutide reached 3.51 billion U.S. dollars, which is still in rapid growth, and new indications will further increase sales expectations.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
A Faster Route to Diabetes Drug Chemistry
-
Study Finds Semaglutide Lower Suicide Ideation Risk Compared to Other Diabetes and Obesity Medications
-
Are GLP-1 Receptor Agonists Linked to Hair Loss and Suicidal Thoughts?
-
Can New Entrants Succeed in the Competitive GLP-1 Drug Market?
-
'Weight loss needle' is coming to China soon! Why is Semaglutide the best GLP-1 student?
-
$60 billion market size! Market analysis of diabetes therapeutics
-
Cure diabetes and obesity with printed materials? Novo Nordisk Introduces Cell Therapy for $2.6 billion
-
The different paths of Chinese and foreign diabetes giants: double males and double bears
-
Semaglutide once a week for the treatment of adolescent obesity Phase III results appear in the New England Journal of Medicine: significantly reduce BMI
-
Semaglutide: Another phenomenon-level new drug, breaking one billion in 'seconds', and the 'weight loss' market is basically out of stock
Recommend Reading
-
![“No Artificial Colors” Gets Redefined—Why FDA’s Labeling Shift Is Roiling the Food Additive World]()
“No Artificial Colors” Gets Redefined—Why FDA’s Labeling Shift Is Roiling the Food Additive World
-
![South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%]()
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
![FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives]()
FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives
-
![China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle]()
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
![U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years]()
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
![Cyclohexane Market Supply and Demand Balance, Operating Steadily in China]()
Cyclohexane Market Supply and Demand Balance, Operating Steadily in China
-
![Weak and Volatile Ethanol Market in China]()
Weak and Volatile Ethanol Market in China
-
![This week, the price of China's 180CST fuel oil has fallen from its high position]()
This week, the price of China's 180CST fuel oil has fallen from its high position
-
![This Week, the Chinese Polymeric MDI Market Showed a Weak Decline (4.20-4.24)]()
This Week, the Chinese Polymeric MDI Market Showed a Weak Decline (4.20-4.24)
-
![This Week, Anhydrous Hydrogen Fluoride Prices Remain Steady at High Levels in China (4.20-4.24)]()
This Week, Anhydrous Hydrogen Fluoride Prices Remain Steady at High Levels in China (4.20-4.24)
